Search

Your search keyword '"J. Sahhar"' showing total 73 results

Search Constraints

Start Over You searched for: Author "J. Sahhar" Remove constraint Author: "J. Sahhar" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
73 results on '"J. Sahhar"'

Search Results

1. The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes

2. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis

Catalog

Books, media, physical & digital resources

3. S.8.1 An immunochip-based interrogation of scleroderma susceptibility variants

4. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis

5. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis

6. Impact of Season, Environmental Temperature, and Humidity on Raynaud Phenomenon in an Australian Systemic Sclerosis Cohort.

7. Progression and clinical implications of frailty in patients with systemic sclerosis.

8. Prevalence and Outcomes of Gastrointestinal Manifestations in an Australian Scleroderma Cohort.

9. The frequency and clinical associations of opioid use in systemic sclerosis.

10. Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis.

11. Comparison of Three Physician Global Assessment Instruments in Systemic Sclerosis.

12. Investigating the trajectory of functional disability in systemic sclerosis: group-based trajectory modelling of the Health Assessment Questionnaire-Disability Index.

13. Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy.

14. The burden and determinants of fatigue in incident and prevalent systemic sclerosis.

15. Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease.

16. Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

17. Quantifying the Need for Specialist Palliative Care Management in Patients With Systemic Sclerosis.

18. Inflammatory Arthritis in Systemic Sclerosis: Its Epidemiology, Associations, and Morbidity.

19. Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis.

20. Proximal weakness and creatine kinase elevation in systemic sclerosis: Clinical correlates, prognosis and functional implications.

21. Frequency and implications of malnutrition in systemic sclerosis.

22. Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis.

23. The effect of calcium channel blockers on digital ulcers in systemic sclerosis: data from a prospective cohort study.

24. Impact of the COVID-19 Pandemic on Health Care Access and Diagnosis of Pulmonary Arterial Hypertension Among Patients With Systemic Sclerosis.

25. Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling.

26. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.

27. The emerging association between bronchiectasis and systemic sclerosis: assessing prevalence and potential causality.

28. Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis.

29. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.

30. Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes.

31. 47XXY and 47XXX in Scleroderma and Myositis.

32. Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.

33. Screening rates and prevalence of osteoporosis in a real-world, Australian systemic sclerosis cohort.

34. Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients.

35. Determinants of left ventricular structure, filling and long axis function in systemic sclerosis.

36. Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes.

37. Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension.

38. Performance of the 2017 EUSTAR activity index in an scleroderma cohort.

39. Occupational silica exposure in an Australian systemic sclerosis cohort.

40. Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis.

41. Can Patient-Reported Symptoms Be Used to Measure Disease Activity in Systemic Sclerosis?

42. The clinical and economic burden of systemic sclerosis related interstitial lung disease.

43. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden.

44. The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia.

45. IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis.

46. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons.

47. Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension: alternative scenario analyses.

48. Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis.

49. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.

50. Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis.